XFOR — X4 Pharmaceuticals, Inc. stock price, charts and financials

QT79X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
4.49
-0.15-3.34%
OverviewShort InterestFilings
XFORQT79X4 Pharmaceuticals, Inc.·NASDAQ
4.49-3.34%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.33%$15.48MESO+4.96%$16.73ZBIO-1.46%$31.96GHRS-2.07%$29.64TSHA-0.69%$6.51STOK-1.46%$32.23ABCL+31.03%$9.08VRDN-2.29%$23.05
Snapshot
Index-P/E-EPS (ttm)-4.54Insider Own35.06%Shs Outstand94.32MPerf Week16.58%
Market Cap437.64MForward P/E-EPS next Y-0.75Insider Trans-0.08%Shs Float57.53MPerf Month17.17%
Enterprise Value243.01MPEG-EPS next Q-Inst Own-Short Float11.30%Perf Quarter8.16%
Income-67.31MP/S27.62EPS this Y84.36%Inst Trans-Short Ratio10.41Perf Half Y26.78%
Sales15.85MP/B3.77EPS next Y-5.07%ROA-35.62%Short Interest6.50MPerf YTD16.00%
Book/sh-P/C-EPS next 5Y-ROE-63.05%52W High4.67 -3.93%Perf Year193.67%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-37.53%52W Low1.30 243.70%Perf 3Y-91.11%
Dividend Est.-EV/EBITDA-Sales past 3/5Y- 63.45%Gross Margin81.22%Volatility6.50% 6.50%Perf 5Y-97.31%
Dividend TTM-EV/Sales15.34EPS Y/Y TTM18.78%Oper. Margin-554.71%ATR (14)0.26Perf 10Y-
Dividend Ex-Date-Quick Ratio11.02Sales Y/Y TTM-Profit Margin-568.80%RSI (14)66.87Recom2.08
Dividend Gr. 3/5Y-Current Ratio11.30EPS Q/Q-SMA2016.41%Beta0.41Target Price11.67
Payout0.00%Debt/Eq0.00Sales Q/Q-89.66%SMA5015.23%Rel Volume2.32Prev Close4.64
Employees45LT Debt/Eq0.41EarningsOct 29SMA20019.21%Avg Volume687.37KPrice4.49
IPO DateNov 16, 2017Option/ShortYes / YesEPS/Sales Surpr.-2.20% -15.37%Net Debt/EBITDA2.45Volume1,597,012Change-3.34%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-10-26InitiatedWells FargoOverweight$11
Jun-02-26InitiatedLeerinkOutperform$12
Mar-09-26InitiatedGuggenheimBuy$12
Dec-05-25ReiteratedStifel Nicolaus$7.50 → $10
Nov-05-25ReiteratedStifel Nicolaus$9.00 → $7.50
Aug-29-25ReiteratedStifel Nicolaus$9.00
Aug-13-25ReiteratedHC Wainwright & Co.Buy$5.00 → $3.50
Dec-12-23DowngradeB. Riley SecuritiesBuy → Neutral
Dec-22-22ReiteratedCantor FitzgeraldOverweight$3.00
Nov-30-22ReiteratedHC Wainwright & Co.Buy$5.00
Latest News
Company

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue17353——————
Cost of Goods Sold Incl. D&A361——————
Gross Profit12292——————
Selling, General and Administrative Excl. Other354462——————
Research and Development657282——————
Other Operating Expense10-106——————
Operating Income-88-87-36——————
Interest Expense899——————
Unusual Expense
—————————
Non-Operating Income (Expense)6178——————
Net Income Before Taxes-90-79-37——————
Income Taxes
000——————
Consolidated Net Income-90-79-37——————
Net Income From Continuing Operations-90-79-37——————
Net Income-90-79-37——————
EPS (Recurring)-1.20-1.87-5.59——————
EPS (Basic, Before Extraordinaries)-1.20-1.87-5.59——————
EPS (Diluted)-1.20-1.87-5.59——————
EBITDA-80-69-28——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio33.244.8051.36——————
Gross Margin70.5982.8666.67——————
Operating Margin-517.65-248.57-1,200.00——————
Net Margin-529.41-225.71-1,233.33——————
Shares Outstanding126427——————
Market Capitalization565168154——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$5.16$4.10$3.04$1.99$0.93● Close Price0.00K62.50K125.00K187.50K250.00KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
KIRSKE DAVIDChief Financial OfficerJun 30 '26Sale4.268,54336,428167,750Jul 01
KIRSKE DAVIDChief Financial OfficerMay 12 '26Sale4.2916,96172,820176,293May 13
Craig Adam RExecutive ChairmanOct 23 '25Buy2.9086,206249,997376,087Oct 27
Baldry MarkChief Commercial OfficerMay 16 '25Buy2.481,0322,56125,337May 20
Baldry MarkChief Commercial OfficerNov 15 '24Buy0.3413,4044,598129,173Feb 14
Baldry MarkChief Commercial OfficerMay 17 '24Buy0.6821,64614,654115,769Feb 14
Ragan PaulaPresident and CEOJan 24 '25Sale0.4576,47334,7191,087,386Jan 27
Mostafa Adam S.Chief Financial OfficerJan 24 '25Sale0.4574,77333,9470Jan 27
Baldry MarkChief Commercial OfficerJan 24 '25Sale0.4529,15913,24194,123Jan 27
DiBiase MaryChief Operating OfficerJan 24 '25Sale0.4522,25810,094490,980Jan 27
Arbet-Engels ChristopheChief Medical OfficerJan 24 '25Sale0.4511,6245,28414,207Jan 27
Ragan PaulaPresident and CEONov 15 '24Sale0.3931,89712,583993,919Nov 19
Ragan PaulaPresident and CEOOct 15 '24Sale0.5631,89717,9261,025,816Oct 16
Ragan PaulaPresident and CEOOct 07 '24Sale0.55239,436131,5221,057,713Oct 08
Mostafa Adam S.Chief Financial OfficerOct 07 '24Sale0.55230,645126,9010Oct 08
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.